MGNX MacroGenics Inc.: מקדם חוב לטווח ארוך להון

MacroGenics, Inc. (MGNX) growth relies on licensing payments and the development of targeted antibodies. The ratio of long-term debt to equity on this GURU.Markets platform chart demonstrates capital dynamics, where the 4.67 mark serves as a key metric. The company's stability depends on test results and liquidity, while its environmental profile is maintained through the filtration of laboratory emissions and logistics optimization.

For the biotechnology sector, where MacroGenics, Inc. (MGNX) develops precision cancer antibodies, the long-term debt-to-equity ratio determines the financial sustainability of innovation. This metric compares liabilities with maturities exceeding one year against shareholders' equity. The current long-term debt-to-equity ratio is 4.67. A low level for this index minimizes default risk during prolonged R&D cycles. Such a balance sheet structure confirms high business autonomy.